Curated news and analysis on clinical trials, drug approvals, and medical research.
Flow chemistry, laboratory mixer, and industrial extruder markets are projected to grow significantly through 2035, driven by pharmaceutical continuous manufacturing, high R&D funding, and sustainability trends. Flow chemistry is expected to reach $12 billion, while laboratory mixers could hit $29.6 billion. Key players include Merck KGaA, BASF, and Lonza.
FDA approved Trodelvy for first-line metastatic triple-negative breast cancer; EMA's CHMP also recommended Trodelvy plus Keytruda for PD-L1-positive patients. Phase 3 trials showed significant reductions in the risk of disease progression or death.
A rare BTK A428D mutation causes resistance to all BTK-targeted therapies, finds a new study. China is reviewing the first CAR-T therapy for gastric cancer, and research reveals why BET inhibitors fail and targets AML's DNMT3A mutation.
Moderna shares fell 11% on Friday, eyeing their worst week since August 2025 after a June surge. An FDA panel voted 9-0 for its mRNA-1010 flu vaccine, with a decision due by August 5.
AviadoBio licensed Apertura's TfR1 CapX capsid for CNS gene therapies, including AVB-406 for Alzheimer's. ASGCT 2026 presentations will highlight clinical-scale manufacturing and broad brain and spinal cord delivery.
The Biotechnology Sciences and Engineering Building at UTSA will experience three planned utility outages: a steam outage on Feb. 19, a water outage on May 23, and a multi-day steam outage from July 31 to Aug. 2. These outages are necessary for repairs and maintenance, temporarily affecting lab equipment and water access.
An ultrasensitive test detects TDP-43 seeds in CSF to diagnose FTLD-TDP. At-home blood tests show promise for remote dementia triage, but primary care use of plasma biomarkers remains limited.
A phase 3 trial of azacitidine and chidamide plus CHOP in untreated PTCL showed a significant overall survival improvement but no significant gains in response rate or progression-free survival. The study suggests molecular profiling could guide future therapies.
In AQP4-positive NMOSD, relapse within 4 weeks of meningococcal vaccination was uncommon (3.3% overall). Findings support vaccination as a generally acceptable prerequisite before C5 inhibitor therapy, with causality still unclear.
Engineered extracellular vesicles deliver IL-2 and therapeutic antibodies with precision, reducing systemic toxicity and targeting inflamed tissues in autoimmune disease, cancer, and inflammatory bowel disease. Microfluidic electroporation enables efficient IL-2 loading, while exosome nanovesicles show efficacy in preclinical colitis models.
The FDA launched two pilots to boost domestic manufacturing: PreCheck selected seven companies for earlier engagement, and a CVM pilot prioritizes animal drug applications with US-made ingredients.
Celltrion released new post-hoc analysis from its phase 3 trial of Remsima SC in IBD patients at the ECCO 2026 congress. The data showed rapid clinical response after treatment gaps and maintained efficacy over 102 weeks. The company also highlighted its unique offering of infliximab in three formulations.
Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, while the USPTO allowed a patent for biomarker-guided use of LP-184 in multiple cancers. LP-284 showed a complete metabolic response in a Phase 1 DLBCL patient, and LP-184 demonstrated a 45% disease control rate in advanced solid tumors.
The White House issued a report urging federal agencies to fund scientific research beyond university labs, favoring individual researchers and multiyear grants. Critics call the plan a rhetorical move that could undermine the existing research enterprise, while the administration frames it as necessary for complex, large-team science.
Two new studies clarify how Epstein-Barr virus may trigger multiple sclerosis: one shows a doubled CD4+ T cell response in untreated patients, while another reveals EBV-activated B cells cause brain inflammation in mice. Insights point to potential therapies targeting EBV-specific immune activity.
Eli Lilly will file its triple-agonist obesity drug retatrutide in early 2027 via a Biologics License Application, seeking stronger market protections. Positive Phase 3 results showed up to 22.6% weight loss, while cardiovascular safety data raised some questions.
Researchers report advances in drug discovery chemistry, including a stereoselective THF synthesis, an SF6-based phosphonylation method, a large androgen receptor binding screen, and improved oligonucleotide chromatography.
A sustained telehealth program combining counseling and nicotine replacement therapy boosted 6-month smoking abstinence to 28.4% vs. 14.7% with quitline referral, a national trial found. The intervention was well-engaged and satisfied patients.
Lonza announced a licensing agreement with Engitix to develop ADCs using its technology platform, alongside an expansion of its Advanced Synthesis offering that integrates GlycoConnect, HydraSpace, and toxSYN technologies. The Oss site has been upgraded to support bioconjugate R&D and pilot toxicology supply.
Stony Brook University and SWFT Labs expanded a partnership to commercialize cellulose nanomaterials as plastic alternatives, advancing the 'Silicon Island' vision for Long Island as a tech hub. The effort is backed by state quantum and biotech investments.
